2-[3-[[4-(Cyclopropylmethoxymethyl)-5-[4-(trifluoromethyl)phenyl]-1,2-oxazol-3-yl]methylsulfanyl]phenyl]acetic acid | 915788-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-[[4-(Cyclopropylmethoxymethyl)-5-[4-(trifluoromethyl)phenyl]-1,2-oxazol-3-yl]methylsulfanyl]phenyl]acetic acid
• CAS: 915788-93-1
• 化学式: C₂₄H₂₂F₃NO₄S
• 分子量: 477.504
• InChiKey: UIEPOJBXMGWPHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Pharmaceutical combination comprising vitamin k
  申请人：Inoue Satoshi

  公开号：US20090137614A1

  公开（公告）日：2009-05-28

  It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder.
• PHARMACEUTICAL COMBINATION COMPRISING VITAMIN K
  申请人：INOUE Satoshi

  公开号：US20110028499A1

  公开（公告）日：2011-02-03

  It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder.